Turkish Journal of Hematology Volume: 35 - Issue: 4

More documents

Recommendations

Info

Özcan O, et al: Thiol/Disulfide Balance in Sickle Cell DiseaseTurk J Hematol 2018;35:265-27026. Varma RN, Mankad VN, Phelps DD, Jenkins LD, Suskind RM. Depressederythrocyte glutathione reductase activity in sickle cell disease. Am J ClinNutr 1983;38:884-887.27. Wetterstroem N, Brewer GJ, Warth JA, Mitchinson A, Near K. Relationshipof glutathione levels and Heinz body formation to irreversibly sickled cellsin sickle cell anemia. J Lab Clin Med 1984;103:589-596.28. Griffith OW. Biologic and pharmacologic regulation of mammalianglutathione synthesis. Free Radic Biol Med 1999;27:922-935.29. Ateş İ, Özkayar N, Yılmaz FM, Bayrakçı N, Neşelioğlu S, Erel Ö, YenigünEC, Dede F. Oxidative stress level in patients with chronic kidney disease.Ortadogu Medical Journal 2018;10:45-50.30. Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the centralcontribution of albumin to redox processes. Free Radic Biol Med2013;65:244-253.31. Peters T Jr. All About Albumin: Biochemistry, Genetics, and MedicalApplications. San Diego, Academic Press, 1995.32. Lavoie S, Berger M, Schlögelhofer M, Schäfer MR, Rice S, Kim SW, HesseJ, McGorry PD, Smesny S, Amminger GP. Erythrocyte glutathione levelsas long-term predictor of transition to psychosis. Transl Psychiatry2017;7:e1064.33. Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D, Kaski JC. Ischemiamodifiedalbumin concentrations in patients with peripheral vasculardisease and exercise-induced skeletal muscle ischemia. Clin Chem2004;50:1656-1660.34. Montagnana M, Lippi G, Volpe A, Salvagno GL, Biasi D, Caramaschi P, CesareGuidi G. Evaluation of cardiac laboratory markers in patients with systemicsclerosis. Clin Biochem 2006;39:913-917.35. Piwowar A, Knapik-Kordecka M, Warwas M. Ischemia-modified albuminlevel in type 2 diabetes mellitus - Preliminary report. Dis Markers2008;24:311-317.36. Chang D, Sha Q, Zhang X, Liu P, Rong S, Han T, Liu P, Pan H. The evaluationof the oxidative stress parameters in patients with primary angle-closureglaucoma. PLoS One 2011;6:e27218.37. Klings ES, Farber HW. Role of free radicals in the pathogenesis of acutechest syndrome in sickle cell disease. Respir Res 2001;2:280-285.38. Morris CR, Suh JH, Hagar W, Larkin S, Bland DA, Steinberg MH, VichinskyEP, Shigenaga M, Ames B, Kuypers FA, Klings ES. Erythrocyte glutaminedepletion, altered redox environment, and pulmonary hypertension in sicklecell disease. Blood 2008;111:402-410.270
RESEARCH ARTICLEDOI: 10.4274/tjh.2018.0071Turk J Hematol 2018;35:271-276Does Reinfusion of Stem Cell Products on Multiple Days AffectEngraftment?Çoklu Gün Kök Hücre Reinfüzyonu Engrafmanı Etkiler mi?Şerife Solmaz Medeni 1 , Doğuş Türkyılmaz 2 , Celal Acar 1 , Ömür Gökmen Sevindik 3 , Faize Yüksel 2 , Özden Pişkin 2 ,Mehmet Ali Özcan 2 , Fatih Demirkan 2 , Bülent Ündar 2 , İnci Alacacıoğlu 2 , Güner Hayri Özsan 21University of Health Sciences, İzmir Bozyaka Training and Research Hospital, Clinic of Hematology, İzmir, Turkey2Dokuz Eylül University Faculty of Medicine, Department of Hematology, İzmir, Turkey3Fırat University Faculty of Medicine, Department of Hematology, Elazığ, TurkeyAbstractObjective: High-doses of melphalan treatment with autologousstem cell transplantation in multiple myeloma (MM) remains a majortreatment modality in suitable patients. A minimal dose of 2x10 6 /kgCD34+ cells is preferred to achieve engraftment. Some patients needmultiple leukapheresis procedures to achieve the necessary numberof CD34+ cells, but this can cause a high volume of stem cell productthat cannot be given in a single day. Whether or not the number ofinfusion days affects engraftment has not been studied before. Weaimed to evaluate the impact of reinfusion of stem cells on multipledays on engraftment results.Materials and Methods: Demographic features, CD34+ cell doses,neutrophil and platelet engraftment days, hospitalization days, andnumber of infusion days of 149 autologous transplantations of 143MM patients were evaluated retrospectively.Results: The data of 143 MM patients who were transplanted wereanalyzed retrospectively. Median age was 55±8.5 (range: 26-70) yearswith a male/female ratio of 91/58. Hospitalization days for all patientswere 24±6 (range: 14-50) days. Mean CD34+ cell number was (7.5±5.3)x10 6 /kg (range: 1.5-31x10 6 /kg). CD34+ cells were reinfused in 1 day in80.5% (n=120) of the patients, 2 days in 18.2% of the patients (n=27),and 3 days in 1.3% of the patients (n=2). For 29 patients, reinfusionwas applied in more than 1 day because of the high volume of stemcell product. We did not see any dimethyl sulfoxide toxicity, cardiacarrhythmia, or volume overload complications. Hypertensive attacksduring infusion were easily controlled by furosemide treatment. In thegroup with multiple infusions, the infused CD34+ cell numbers had amean of (4.8±2.8)x10 6 /kg, and in the single infusion group the meanwas (8.1±5.5)x10 6 /kg. There were no statistical differences betweenthe two groups regarding platelet and neutrophil engraftment days(p=0.850, r=0.820 and p=0.500, r=0.440). There was no statisticaldifference between the two groups for hospitalization days (p=0.060,r=0.050).ÖzAmaç: Multipl myelom (MM) hastalarında yüksek doz melfalan veotolog kök hücre nakli fit hastalarda hala majör tedavi modalitesidir.Yeterli engrafman için en az 2x10 6 /kg CD34+ hücre dozu tercih edilir.Bazı hastalar gerekli sayıda CD34+ hücre sayısına ulaşmak için çoklulökoferez prosedürüne ihtiyaç duyarlar, fakat bu tek günde verilemeyenyüksek miktarda kök hücre ürününe neden olabilir. İnfüzyon günüsayısının engrafmanı etkileyip etkilemediği daha önce çalışılmamıştır.Çoklu gün kök hücre reinfüzyonunun engrafman sonuçlarına etkisinideğerlendirmeyi amaçladık.Gereç ve Yöntemler: Demografik özellikler, CD34+ hücre dozları,nötrofil ve trombosit engrafman günleri, hastanede yatış günleri ile143 MM hastasının 149 otolog transplantasyonunun infüzyon günsayısı retrospektif olarak değerlendirildi.Bulgular: Transplantasyon yapılan 143 MM hastasının verileriretrospektif olarak incelendi. Ortalama yaş 55±8,5 idi (en düşük:26 - en fazla: 70) ve erkek/kadın oranı 91/58 idi. Tüm hastalar içinhastanede kalış günleri 24±6 gündü (en düşük: 14 - en fazla: 50).Ortalama CD34+ hücre sayısı (7,5±5,3)x10 6 /kg idi (en düşük: 1,5x10 6 /kg - en yüksek: 31x10 6 /kg). Hastaların %80,5’inde (n=120)tek günde CD34+ hücre reinfüzyon, hastaların %18,2’sinde (n=27)2 günde CD34+ hücre reinfüzyon ve hastaların %1,3’ünde (n=2) 3günde CD34+ hücre reinfüzyon yapılmıştı. Yirmi dokuz hastada yüksekhacimde kök hücre ürünü olması nedeniyle 1 günden fazla reinfüzyonuygulandı. Herhangi bir dimetil sülfoksit toksisitesi, kardiyak aritmiveya hacim yükü komplikasyonları görmedik. İnfüzyon sırasındahipertansif ataklar furosemid tedavisi ile kolayca kontrol altına alındı.CD34+ hücre sayıları ortalama çoklu gün reinfüzyonu yapılan grupta(4,8±2,8)x10 6 /kg ve tek gün reinfüzyon grubunda ise (8,1±5,5)x10 6 /kg idi. İki grup arasında trombosit ve nötrofil engrafman günleriaçısından istatistiksel olarak anlamlı fark yoktu (p=0,850, r=0,820 vep=0,500, r=0,440). İki grup arasında hastanede yatış günleri açısındanistatistiksel fark yoktu (p=0,060, r=0,050).©Copyright 2018 by Turkish Society of HematologyTurkish Journal of Hematology, Published by Galenos Publishing HouseAddress for Correspondence/Yazışma Adresi: Şerife SOLMAZ MEDENİ, M.D.,University of Health Sciences, İzmir Bozyaka Training and Research Hospital, Clinic of Hematology, İzmir, TurkeyPhone : +90 232 250 50 50E-mail : solmazserife@yahoo.com ORCID-ID: orcid.org/0000-0001-7180-3423Received/Geliş tarihi: February 15, 2018Accepted/Kabul tarihi: June 20, 2018271
Page 1:
Volume 35 Issue 4 December 2018 80
Page 4 and 5:
Contact InformationEditorial Corres
Page 6 and 7:
TURKISH JOURNAL OF HEMATOLOGYINSTRU
Page 8 and 9:
Perspectives in Hematology“Perspe
Page 10 and 11:
authors is provided. Each page has
Page 12 and 13:
Letters to the Editor300 The Impact
Page 14 and 15:
Perez-Amill L, et al: CAR-T Cell Th
Page 16 and 17: Perez-Amill L, et al: CAR-T Cell Th
Page 26 and 27: Olcay L, et al: Hematopoiesis in Fa
Page 56 and 57: RESEARCH ARTICLEDOI: 10.4274/tjh.20
Page 58 and 59: Açelya Yılmazer Aktuna, Tendency
Page 60 and 61: Açelya Yılmazer Aktuna, Tendency
Page 62 and 63: Özcan O, et al: Thiol/Disulfide Ba
Page 64 and 65: Özcan O, et al: Thiol/Disulfide Ba
Page 68 and 69: Solmaz Medeni S, et al: Does Reinfu
Page 74 and 75: Özkocaman V, et al: Primary Antifu
Page 80 and 81: Cavit Çehreli, Diagnostic Problems
Page 86 and 87: BRIEF REPORTDOI: 10.4274/tjh.2018.0
Page 88 and 89: Benli A, et al: Piperacillin-Tazoba
Page 90 and 91: Benli A, et al: Piperacillin-Tazoba
Page 92 and 93: IMAGES IN HEMATOLOGYDOI: 10.4274/tj
Page 94 and 95: IMAGES IN HEMATOLOGYDOI: 10.4274/tj
Page 96 and 97: LETTERS TO THE EDITORTurk J Hematol
Page 110 and 111: LETTERS TO THE EDITOR Turk J Hemato
Page 112 and 113: AUTHOR INDEX 201835 th Volume Index
Page 114 and 115: AUTHOR INDEX 2018Olga Meltem Akay..
Page 116 and 117:
SUBJECT INDEX 2018Basophilic stippl
Page 118 and 119:
SUBJECT INDEX 2018Gluteal lymphoma
Page 120 and 121:
SUBJECT INDEX 2018Diffuse large B-c
Page 122 and 123:
SUBJECT INDEX 2018Thalassemia / Tal
show all

Turkish Journal of Hematology Volume: 35 - Issue: 4

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?